Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 25-36 of 211 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 25-36 of 211 studies
-
Restore CFTR ProteinClosed to Enrollment
Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part A) , protocol number Vertex VX20-445-111 Part AThis study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.
-
Age:
2 Years to 5 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
53 days
-
-
Restore CFTR ProteinClosed to Enrollment
Study of ELX-02 in adults with cystic fibrosis who have at least one G542X mutation , protocol number Eloxx EL-012 - Cohorts 1 to 4This study will look at the safety and tolerability of ELX-02 and how the body processes the drug, a molecule intended to restore CFTR function. Multiple doses of ELX-02 will be tested in adults with cystic fibrosis who have at least one G542X mutation.
-
Age:
18 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
15
-
Length of Participation:
15 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
Study of ABBV-3067 and ABBV-2222 in adults with cystic fibrosis who have two copies of the F508del mutation , protocol number AbbVie M19-530This study will look at the safety and effectiveness of ABBV-3067, a CFTR modulator intended to help CFTR protein function closer to normal. ABBV-3067 will be tested alone and in combination with another CFTR modulator, ABBV-2222.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
5
-
Length of Participation:
3 months
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of lumacaftor/ivacaftor (Orkambi®) in babies with two copies of the F508del CFTR mutation (Part B) , protocol number Vertex VX-16-809-122 Part BThis study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drug lumacaftor/ivacaftor (Orkambi®) and its effect on the body. It is for babies ages 1 to less than 2 years old who have cystic fibrosis and two copies of the F508del CFTR mutation.
-
Age:
1 Years to 2 Years
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
11
-
Length of Participation:
38 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of lumacaftor/ivacaftor (Orkambi®) in babies with two copies of the F508del CFTR mutation , protocol number Vertex VX-16-809-122 Part AThis study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drug lumacaftor/ivacaftor (Orkambi®) and its effect on the body. It is for babies ages 1 to less than 2 years old who have cystic fibrosis and two copies of the F508del CFTR mutation.
-
Age:
1 Years to 2 Years
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
35 days
-
-
Restore CFTR ProteinClosed to Enrollment
RESTORE-CF: Phase 1/2 study of MRT5005 drug in adults with cystic fibrosis (Parts A, B and B Expansion) , protocol number Translate Bio MRT5005-101This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.
-
Age:
18 Years and Older
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
50 to 90%
-
Number of Visits:
21
-
Length of Participation:
1 years
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation , protocol number Vertex VX-770-126This open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.
-
Age:
Less than 25 Months
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
18
-
Length of Participation:
128 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 1/2 study of PTI-801 drug in healthy adults and then in adults with cystic fibrosis , protocol number Proteostasis PTI-801-01This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug PTI-801.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
30 days
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of ivacaftor in babies who have a CFTR gating mutation , protocol number Vertex VX15-770-124This two-part, open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of ivacaftor, as well as how the body processes the drug, in babies who have a CFTR gating mutation.
-
Age:
Less than 13 Months
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
24 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
SNO7: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
12 weeks
-
-
Anti-InflammatoryClosed to Enrollment
Study of INS1007/brensocatib tablets in adults with CF , protocol number Insmed INS1007-211This study will look at the safety, tolerability, and how the body processes INS1007/brensocatib tablets, a drug intended to reduce inflammation.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
56 days
-
-
Anti-InflammatoryClosed to Enrollment
Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa , protocol number Calithera CX-280-202This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung and reduce inflammation. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
6
-
Length of Participation:
2 months
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More